Shorted
Anatara Lifesciences logo
ANR
Pharmaceuticals, Biotechnology & Life Sciences

Anatara Lifesciences

Short interest
0.00%
−0.01 pp 30d
as of 14 Oct 2024
Reported shorts
558
Shares on issue
192.894M

Anatara Lifesciences (ANR) company profile

Profile, insiders and operations

Company

AI-generated research profile of Anatara Lifesciences

biotechnology
gastrointestinal health
oral therapeutics
animal health
non-antibiotic solutions

Anatara Lifesciences Ltd focuses on developing non-antibiotic oral solutions targeting gastrointestinal diseases for both humans and animals. The company operates in the biotechnology sector and strives to harness novel therapeutic compositions to address significant unmet medical needs. Its strategic emphasis on non-antibiotic approaches positions it as an innovative player in the digestive health market.

Director trades

12 trades recorded

DateDirectorTypeSharesPriceValue
2026-08-24John Michailidis
exercise options
359,640--
2026-08-24Unknown Director
buy
---
2025-12-11David Brookes
sell
932,143--
2025-12-11Unknown Director
buy
---
2025-11-27Unknown Director
buy
---
2025-11-26David Brookes
other
3,333,334$0.012$40,000
2024-12-24Unknown Director
buy
---
2024-12-23David Brookes
buy
500,000$0.050$25,000
2024-11-20Unknown Director
buy
---
2024-11-18John Michailidis
other
359,640--
2024-07-12Unknown Director
buy
---
2024-07-09David Brookes
other
4,000,000$0.015$60,000

ANR intelligence dossier

Public-source evidence for this company, with industry drill-up links.

  • Tax paid and taxable income records
  • Government contracts and public money
  • Emissions and trade exposure
  • Political donations and lobbying links
Sign in to unlock the dossierFree account · no card required